近日，陆道培医院陆佩华院长作为第一作者和通讯作者，在国际血液学权威期刊 Blood（IF = 21）在线发表了题为「Nanobody-based Naturally Selected CD7-Targeted Chimeric Antigen ...

其中罗氏的用于治疗血友病的Hemlibra全球销量最高，2024年销售额达到45.03亿瑞士法郎（约53.61亿美元）。其次是罗氏的眼科药物Vabysmo增长迅速，2024年销售额为38.64亿瑞士法郎（约46.0亿美元），加上Columvi和Lun ...

Integrating best practices in AI, genomics, cell culture, and laboratory techniques together contribute to protein expression success.

引言在消化肿瘤中，细胞疗法的临床证据依旧有限。CLDN18.2 是胃癌中引发关注的新兴靶点，靶向 CLDN18.2 的嵌合抗原受体 T ...

Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

叠氮修饰的 M1 型 TAM 外泌体，CD47 和 SIRPα 抗体通过 pH 敏感键偶联到外泌体表面 TAM（肿瘤相关巨噬细胞）外泌体来自 M1 型 TAM（促炎型巨噬细胞），这些外泌体具有较强的免疫刺激功能，可以增强免疫系统的抗肿瘤反应，M1 型 TAM 外泌体在肿瘤微环境中通过释放 ...

We established a model that allowed us to test the BC1cCAR scFv functionality independently. A CML cell line, K562, negative for myeloma markers was induced to express either CS1 (CS1-K562 ...

全面布局TCE赛道，维立志博或成国内TCE第一股,细胞,t细胞,特异性,抗体,实体瘤,免疫 ...

After hours: February 28 at 6:42:48 PM EST Loading Chart for ZURA ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, ...

Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane domain (TMD) between the ...